Baker Bros. Advisors LP bought $262k of TRDA
owner at Entrada Therapeutics, Inc.. 28,867 shares at an average of $9.07, traded Nov 20, 2025, filed Nov 24, 2025.
Score components
- +12Role10% owner
- +13Trade size$262k at market
- +3Relative to holdingsHoldings up 8%
- +8Price context58% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-293698, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 20, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +1,213 | $9.07 | $11k | 380,152 | Nov 24, 2025 |
| Nov 20, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +13,386 | $9.07 | $121k | 4,678,310 | Nov 24, 2025 |
| Nov 20, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +1,186 | $9.07 | $11k | 381,338 | Nov 24, 2025 |
| Nov 20, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +13,082 | $9.07 | $119k | 4,691,392 | Nov 24, 2025 |
Related signals
Other insiders at Entrada Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $1.9M 259,837 shares | -6% | |
| 45Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $1.9M 259,837 shares | -6% | |
| 40Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $617k 86,482 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $617k 86,482 shares | -2% | |
| 26Weak | Entrada Therapeutics, Inc. | Kory James Wentworth Chief Financial Officer | $89k 8,910 shares | -7% | |
| 52Moderate | Entrada Therapeutics, Inc. | 5AM Ventures V, L.P. owner | $1.8M 200,000 shares | -6% | |
| 55Moderate | Entrada Therapeutics, Inc. | Kush Parmar director, owner | $1.8M 200,000 shares | -6% | |
| 46Moderate | TRDAbuy Entrada Therapeutics, Inc. | Baker Bros. Advisors LP owner | $1.4M 178,044 shares | +49% | |
| 32Weak | Entrada Therapeutics, Inc. | 5AM Ventures V, L.P. owner | $203k 27,000 shares | -1% | |
| 35Weak | Entrada Therapeutics, Inc. | Kush Parmar director, owner | $203k 27,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.